Comparison of the clinical effect of atorvastatin ointment with rosuvastatin in patients with psoriasis

Phase 2

Recruiting

Conditions: Psoriasis skin disease.
Psoriasis vulgaris
L40.0

Registration Number: IRCT20240220061059N1

Lead Sponsor: Yazd University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

over 18 years old
Psoriasis patients referred to the skin outpatient clinic of Shahada Mehrab Hospital

Exclusion Criteria

pregnancy or lactation
Patients suffering from several skin diseases at the same time
Patients using non-steroidal anti-inflammatory drugs daily or more than 5 times a week

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome of disease severity based on Psoriasis Area Severity Index (PASI). Timepoint: The measurement of the primary outcome variable is based on time intervals 0, and in weeks 4, 8, and 12 after the start of the intervention. Method of measurement: The primary outcome variable is evaluated using the Psoriasis Area Severity Index criterion, which ranges from 0 to 72. The effectiveness of the treatment is in the form of changes in the PASI criterion from baseline to the last week. A complete response is when the PASI standard decreases to zero in the last week, a marked response is when the PASI standard is reduced by more than 75% from the baseline, a moderate response is when the standard PASI should decrease between 50 and 74%; A slight response is when the PASI score decreases by less than 50%. No response is when the lesions do not change during twelve weeks of treatment.

Secondary Outcome Measures

Name	Time	Method
The secondary outcome is that at the beginning of visiting the clinic and entering the study, and at the end of the twelfth week, a photo of the lesions is taken, and the degree of improvement in the lesions is scored from zero to ten through a visual analog scale. (zero for lesions that have not improved at all and ten for the best response to treatment). Timepoint: At the beginning of the study and at the end of the twelfth week after the start of the intervention, the secondary outcome is evaluated. Method of measurement: The rate of recovery in the process of lesions through visual analog scale.